Strategic Acquisition Agno Pharma's recent acquisition of The Lubrizol Corporation's Particle Sciences division demonstrates its commitment to expanding capabilities in complex drug delivery systems and topical formulations, presenting opportunities to collaborate on advanced formulation development projects.

Global Manufacturing Capabilities With GMP-compliant facilities and sterile manufacturing expertise in North America and Europe, Agno Pharma is positioned to serve multinational pharmaceutical companies seeking reliable contract manufacturing partners for both development and commercialization stages.

Niche Product Focus Specializing in highly potent APIs, sterile APIs, and complex injectables, Agno Pharma offers tailored manufacturing solutions, making it a valuable partner for companies developing advanced, high-value therapeutic modalities that require specialized manufacturing infrastructure.

Growth Potential Operating within the mid-sized segment with a revenue between 10 to 25 million dollars, Agno Pharma is poised for expansion through strategic partnerships and leveraging its recent acquisition to increase market share in the CDMO sector.

Technology & Compliance Utilizing advanced IT infrastructure and maintaining US-FDA inspected facilities ensures high-quality, compliant manufacturing, which is critical for attracting clients looking for dependable regulatory adherence in complex drug manufacturing.